Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2020.07.089
Abstract: Abstract Background Finite clinical data and understanding of COVID-19 immunopathology has led to limited, opinion-based recommendations for management of immune-mediated inflammatory disease (IMID) patients on immunosuppressive (IS) therapeutics. Objective Determine if IS therapeutic type impacts… read more here.
Keywords: covid; imid patients; immune mediated; mediated inflammatory ... See more keywords
POS0055 SARS-COV-2 OUTBREAK IN AUTOIMMUNE DISEASES: THE EURO-COVIMID STUDY
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.3368
Abstract: Background: Coronavirus disease 2019 (COVID-19), has raised several questions in patients with immune-mediated inflammatory diseases (IMID). Whether the seroprevalence and factors associated with symptomatic COVID-19 are similar in IMID patients and in the general population… read more here.
Keywords: imid patients; study; sars cov; covid ... See more keywords
Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.915578
Abstract: Background Pharmacotherapeutic management of immune-mediated inflammatory diseases (IMID) has become more complex due to the development of new treatments, such as biological therapies. Mobile health, especially apps, can provide IMID patients with greater autonomy and… read more here.
Keywords: medication; immune mediated; app; mediated inflammatory ... See more keywords